Adding Relatlimab to First-Line Nivolumab and Chemotherapy Demonstrates Clinical Benefit in Advanced Non-Small Cell Lung Cancer
Nicolas Girard, MD, PhD, Curie Institute, Paris, France, discusses results from the phase 2 RELATIVITY-104 study which demonstrated that nivolumab plus relatlimab and platinum-doublet chemotherapy improved clinical benefit compared to nivolumab and platinum-doublet chemotherapy alone among patients with advanced or recurrent non-small cell lung cancer (NSCLC).
Dr Girard presented these results at the 2024 European Society of Medical Oncology (ESMO) Congress in Barcelona, Spain.
Source:
Girard N, Burotto M, Paz-Ares LG, et al. Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study. Presented at 2024 ESMO Congress. September 13-17, 2024. Abstract LBA53